NGNENasdaqPharmaceutical PreparationsFiscal year ends December 31

Neurogene Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026

$24.17+0.92 (+3.96%)

Close on Oct 19, 2026

Market cap: $545.08M
P/E (TTM): –
Dividend yield: –

Community

Notes and questions about Neurogene from other investors

No posts about NGNE yet

Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Where these numbers come from

Parsed from the XBRL in Neurogene's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-4 reverse split on Dec 19, 2023
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is NGNE.

Revenue growth-100.0% · median -38.6%

Company	Revenue	Growth
CAMP	$4.22M	+40.2%
KRRO	$2.38M	-62.1%
OVID	$1.58M	-76.2%
RLYB	$646.00K	-15.1%
NGNE	$0	-100.0%
SPRB	–	–

Company

Next earnings (est.): Nov 12, 2026, after close
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 131
Held by institutions: 86.5%
Auditor: Deloitte & Touche LLP
SEC CIK: 1404644

Advertisement
300 × 250